{
  "schema_version": "chamgap-public-criteria-1.0",
  "title": "Oral vitamin C × endothelial FMD: results differ by population and acute versus sustained dosing",
  "language": "en",
  "translation_date": "2026-10-21",
  "criteria_version": "1.0",
  "criteria_date": "2026-10-06",
  "condition_origin": "Chamgap's own application conditions",
  "method_sources": [
    {
      "id": "M03",
      "version": "Cochrane Handbook 6.5 (2024), chapter updated 2023-08",
      "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-03",
      "section": "§3.1, §3.2.1–3.2.3, MECIR C5/C7/C13",
      "official_principle": "Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions.",
      "review_level": "Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed."
    },
    {
      "id": "M04",
      "version": "Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03",
      "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-04",
      "section": "§4.5, §4.6.1–4.6.3, MECIR C42",
      "official_principle": "Distinguish studies from reports and link them; do not omit a study solely because results are unreported.",
      "review_level": "Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed."
    },
    {
      "id": "M08",
      "version": "Cochrane Handbook 6.5 (2024), chapter updated 2019-10",
      "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-08",
      "section": "§8.1–8.2.3, Table 8.2.a",
      "official_principle": "Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting.",
      "review_level": "Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed."
    },
    {
      "id": "M15",
      "version": "Cochrane Handbook 6.5 (2024), chapter updated 2023-08",
      "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-15",
      "section": "§15.2.4, §15.3.1–15.3.3",
      "official_principle": "Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.",
      "review_level": "Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed."
    },
    {
      "id": "M19",
      "version": "Cochrane Handbook 6.5 (2024), chapter updated 2019-10",
      "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-19",
      "section": "§19.1.2, §19.2.1–19.2.4",
      "official_principle": "Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates.",
      "review_level": "Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed."
    }
  ],
  "status_dictionary": {
    "Partly verified": "Partial information from the stored summary is linked; detailed originals and content review remain incomplete.",
    "Unverified": "Required details cannot be established within the preserved scope. This does not establish absence of effects or studies, or safety.",
    "Review incomplete": "Review of existing content remains incomplete.",
    "Met": "This state is used only within the relevant conditions after material verification and content review. It was not automatically assigned in this work.",
    "Not reported": "Unreported within material actually read. Unread external material is not relabeled as unreported.",
    "Inaccessible": "This means actual access failure. External access was not attempted in this work, so this state was not assigned.",
    "Not applicable": "Used only with an application exception and reason based on the question scope.",
    "Conflicting data": "This requires actual comparison of materials; no new conflict judgment was made in this work.",
    "Insufficient evidence for the conditions": "This indicates gaps in additional material for the selected conditions. Unread material as a whole is not converted into an efficacy grade."
  },
  "requirements": [
    {
      "item_id": "N01",
      "question_type": "Evidence condition",
      "question": "Which FMD question is addressed?",
      "needed": "Oral single-ingredient C and brachial FMD in adults at cardiovascular risk",
      "role": "Required",
      "role_reason": "Material on Oral single-ingredient C and brachial FMD in adults at cardiovascular risk is needed to connect oral single-ingredient treatment, populations, comparators, vascular tests, time points, denominators, precision and harms.",
      "application_exception": "Existing C50, caution, assessment axes and empty values are retained. Oral and intravenous use, single and combined ingredients, acute and sustained outcomes, populations and vascular tests, and percentage points and relative percent are distinguished. No new effects, CIs, denominators, incidence, unique totals or recommended doses are calculated.",
      "criterion": "Original records on Oral single-ingredient C and brachial FMD in adults at cardiovascular risk must link to the same product, population, comparator, test, time point and denominator, distinguishing acute from sustained outcomes and direct findings from supporting or boundary material.",
      "basis": "Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.",
      "condition_origin": "These evidence conditions concern the existing question of oral single-ingredient vitamin C and brachial FMD in adults at cardiovascular risk. They do not establish new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original population, oral product, placebo and brachial FMD endpoint/time tables are needed. Clinical events or artery cleansing are not added. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N02",
      "question_type": "Evidence condition",
      "question": "Are oral single-ingredient C and intravenous or combined products distinguished?",
      "needed": "Ascorbic acid product, salt, excipients and route",
      "role": "Required",
      "role_reason": "Material on Ascorbic acid product, salt, excipients and route is needed to connect oral single-ingredient treatment, populations, comparators, vascular tests, time points, denominators, precision and harms.",
      "application_exception": "Existing C50, caution, assessment axes and empty values are retained. Oral and intravenous use, single and combined ingredients, acute and sustained outcomes, populations and vascular tests, and percentage points and relative percent are distinguished. No new effects, CIs, denominators, incidence, unique totals or recommended doses are calculated.",
      "criterion": "Original records on Ascorbic acid product, salt, excipients and route must link to the same product, population, comparator, test, time point and denominator, distinguishing acute from sustained outcomes and direct findings from supporting or boundary material.",
      "basis": "Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.",
      "condition_origin": "These evidence conditions concern the existing question of oral single-ingredient vitamin C and brachial FMD in adults at cardiovascular risk. They do not establish new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original product, manufacturing, salt, excipient, exposure/adherence and route-specific eligibility tables are needed. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N03",
      "question_type": "Evidence condition",
      "question": "Are acute 2 g, 500 mg/day and 1 g/day kept separate?",
      "needed": "Acute and sustained doses and report-specific products/exposure",
      "role": "Required",
      "role_reason": "Material on Acute and sustained doses and report-specific products/exposure is needed to connect oral single-ingredient treatment, populations, comparators, vascular tests, time points, denominators, precision and harms.",
      "application_exception": "Existing C50, caution, assessment axes and empty values are retained. Oral and intravenous use, single and combined ingredients, acute and sustained outcomes, populations and vascular tests, and percentage points and relative percent are distinguished. No new effects, CIs, denominators, incidence, unique totals or recommended doses are calculated.",
      "criterion": "Original records on Acute and sustained doses and report-specific products/exposure must link to the same product, population, comparator, test, time point and denominator, distinguishing acute from sustained outcomes and direct findings from supporting or boundary material.",
      "basis": "Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.",
      "condition_origin": "These evidence conditions concern the existing question of oral single-ingredient vitamin C and brachial FMD in adults at cardiovascular risk. They do not establish new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Report-specific dosing, time points, actual exposure, products and adherence need to be linked. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N04",
      "question_type": "Evidence condition",
      "question": "Are 2 hours, 30 days, 8 weeks and the total schedule distinguished?",
      "needed": "Acute/sustained time points, crossover periods and total schedule",
      "role": "Required",
      "role_reason": "Material on Acute/sustained time points, crossover periods and total schedule is needed to connect oral single-ingredient treatment, populations, comparators, vascular tests, time points, denominators, precision and harms.",
      "application_exception": "Existing C50, caution, assessment axes and empty values are retained. Oral and intravenous use, single and combined ingredients, acute and sustained outcomes, populations and vascular tests, and percentage points and relative percent are distinguished. No new effects, CIs, denominators, incidence, unique totals or recommended doses are calculated.",
      "criterion": "Original records on Acute/sustained time points, crossover periods and total schedule must link to the same product, population, comparator, test, time point and denominator, distinguishing acute from sustained outcomes and direct findings from supporting or boundary material.",
      "basis": "Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.",
      "condition_origin": "These evidence conditions concern the existing question of oral single-ingredient vitamin C and brachial FMD in adults at cardiovascular risk. They do not establish new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original dosing, washout/placebo periods, assessment, total schedule and post-stopping course are needed. The 20 weeks is not converted into sustained C efficacy. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N05",
      "question_type": "Evidence condition",
      "question": "Are CAD, hypertension, smokers and other vascular tests separated?",
      "needed": "Disease-specific diagnosis/baseline and brachial FMD versus other tests",
      "role": "Required",
      "role_reason": "Material on Disease-specific diagnosis/baseline and brachial FMD versus other tests is needed to connect oral single-ingredient treatment, populations, comparators, vascular tests, time points, denominators, precision and harms.",
      "application_exception": "Existing C50, caution, assessment axes and empty values are retained. Oral and intravenous use, single and combined ingredients, acute and sustained outcomes, populations and vascular tests, and percentage points and relative percent are distinguished. No new effects, CIs, denominators, incidence, unique totals or recommended doses are calculated.",
      "criterion": "Original records on Disease-specific diagnosis/baseline and brachial FMD versus other tests must link to the same product, population, comparator, test, time point and denominator, distinguishing acute from sustained outcomes and direct findings from supporting or boundary material.",
      "basis": "Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.",
      "condition_origin": "These evidence conditions concern the existing question of oral single-ingredient vitamin C and brachial FMD in adults at cardiovascular risk. They do not establish new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original diagnosis, baseline, medication, test/site, formulation and time-specific inclusion tables are needed. A mixed mean is not used as a single-population value. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N06",
      "question_type": "Evidence condition",
      "question": "Are placebo and nonrandomized healthy comparisons distinguished?",
      "needed": "Treatment versus placebo and nonrandomized healthy-control conditions",
      "role": "Required",
      "role_reason": "Material on Treatment versus placebo and nonrandomized healthy-control conditions is needed to connect oral single-ingredient treatment, populations, comparators, vascular tests, time points, denominators, precision and harms.",
      "application_exception": "Existing C50, caution, assessment axes and empty values are retained. Oral and intravenous use, single and combined ingredients, acute and sustained outcomes, populations and vascular tests, and percentage points and relative percent are distinguished. No new effects, CIs, denominators, incidence, unique totals or recommended doses are calculated.",
      "criterion": "Original records on Treatment versus placebo and nonrandomized healthy-control conditions must link to the same product, population, comparator, test, time point and denominator, distinguishing acute from sustained outcomes and direct findings from supporting or boundary material.",
      "basis": "Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.",
      "condition_origin": "These evidence conditions concern the existing question of oral single-ingredient vitamin C and brachial FMD in adults at cardiovascular risk. They do not establish new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original group/condition, allocation, common care and measurement-time tables are needed. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N07",
      "question_type": "Evidence condition",
      "question": "What baseline medication, smoking and diet/care rules applied?",
      "needed": "Group-specific maintained/changed treatment, smoking and additional interventions",
      "role": "Required",
      "role_reason": "Material on Group-specific maintained/changed treatment, smoking and additional interventions is needed to connect oral single-ingredient treatment, populations, comparators, vascular tests, time points, denominators, precision and harms.",
      "application_exception": "Existing C50, caution, assessment axes and empty values are retained. Oral and intravenous use, single and combined ingredients, acute and sustained outcomes, populations and vascular tests, and percentage points and relative percent are distinguished. No new effects, CIs, denominators, incidence, unique totals or recommended doses are calculated.",
      "criterion": "Original records on Group-specific maintained/changed treatment, smoking and additional interventions must link to the same product, population, comparator, test, time point and denominator, distinguishing acute from sustained outcomes and direct findings from supporting or boundary material.",
      "basis": "Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.",
      "condition_origin": "These evidence conditions concern the existing question of oral single-ingredient vitamin C and brachial FMD in adults at cardiovascular risk. They do not establish new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original medication, smoking/lifestyle care, premeasurement rules, changes/adherence and rescue medication are needed. An isolated C effect is not established. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N08",
      "question_type": "Evidence condition",
      "question": "What are the CAD sample of 46 and group-specific analysis denominators?",
      "needed": "R01 allocation, analysis, completion and time-specific FMD denominators",
      "role": "Required",
      "role_reason": "Material on R01 allocation, analysis, completion and time-specific FMD denominators is needed to connect oral single-ingredient treatment, populations, comparators, vascular tests, time points, denominators, precision and harms.",
      "application_exception": "Existing C50, caution, assessment axes and empty values are retained. Oral and intravenous use, single and combined ingredients, acute and sustained outcomes, populations and vascular tests, and percentage points and relative percent are distinguished. No new effects, CIs, denominators, incidence, unique totals or recommended doses are calculated.",
      "criterion": "Original records on R01 allocation, analysis, completion and time-specific FMD denominators must link to the same product, population, comparator, test, time point and denominator, distinguishing acute from sustained outcomes and direct findings from supporting or boundary material.",
      "basis": "Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.",
      "condition_origin": "These evidence conditions concern the existing question of oral single-ingredient vitamin C and brachial FMD in adults at cardiovascular risk. They do not establish new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original flow, group allocation/completion, imaging/measurement missingness and denominators are needed. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N09",
      "question_type": "Evidence condition",
      "question": "Are CAD baseline, acute and 30-day values preserved?",
      "needed": "R01 time- and group-specific FMD% and original ±",
      "role": "Required",
      "role_reason": "Material on R01 time- and group-specific FMD% and original ± is needed to connect oral single-ingredient treatment, populations, comparators, vascular tests, time points, denominators, precision and harms.",
      "application_exception": "Existing C50, caution, assessment axes and empty values are retained. Oral and intravenous use, single and combined ingredients, acute and sustained outcomes, populations and vascular tests, and percentage points and relative percent are distinguished. No new effects, CIs, denominators, incidence, unique totals or recommended doses are calculated.",
      "criterion": "Original records on R01 time- and group-specific FMD% and original ± must link to the same product, population, comparator, test, time point and denominator, distinguishing acute from sustained outcomes and direct findings from supporting or boundary material.",
      "basis": "Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.",
      "condition_origin": "These evidence conditions concern the existing question of oral single-ingredient vitamin C and brachial FMD in adults at cardiovascular risk. They do not establish new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original groups/time points, dispersion, baseline adjustment, denominators and complete results are needed. No new difference, CI or relative improvement is calculated. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N10",
      "question_type": "Evidence condition",
      "question": "Is repeated-measures ANOVA distinguished from each time-specific contrast?",
      "needed": "Original repeated test, interaction and time-specific between-group CIs/P values",
      "role": "Required",
      "role_reason": "Material on Original repeated test, interaction and time-specific between-group CIs/P values is needed to connect oral single-ingredient treatment, populations, comparators, vascular tests, time points, denominators, precision and harms.",
      "application_exception": "Existing C50, caution, assessment axes and empty values are retained. Oral and intravenous use, single and combined ingredients, acute and sustained outcomes, populations and vascular tests, and percentage points and relative percent are distinguished. No new effects, CIs, denominators, incidence, unique totals or recommended doses are calculated.",
      "criterion": "Original records on Original repeated test, interaction and time-specific between-group CIs/P values must link to the same product, population, comparator, test, time point and denominator, distinguishing acute from sustained outcomes and direct findings from supporting or boundary material.",
      "basis": "Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.",
      "condition_origin": "These evidence conditions concern the existing question of oral single-ingredient vitamin C and brachial FMD in adults at cardiovascular risk. They do not establish new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original model, plan, time-specific estimates/CIs and multiplicity information are needed. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N11",
      "question_type": "Evidence condition",
      "question": "Is the existing +3.1 percentage-point calculation distinguished from relative percent and CIs?",
      "needed": "Simple 30-day change difference versus original adjusted effect/interval and units",
      "role": "Required",
      "role_reason": "Material on Simple 30-day change difference versus original adjusted effect/interval and units is needed to connect oral single-ingredient treatment, populations, comparators, vascular tests, time points, denominators, precision and harms.",
      "application_exception": "Existing C50, caution, assessment axes and empty values are retained. Oral and intravenous use, single and combined ingredients, acute and sustained outcomes, populations and vascular tests, and percentage points and relative percent are distinguished. No new effects, CIs, denominators, incidence, unique totals or recommended doses are calculated.",
      "criterion": "Original records on Simple 30-day change difference versus original adjusted effect/interval and units must link to the same product, population, comparator, test, time point and denominator, distinguishing acute from sustained outcomes and direct findings from supporting or boundary material.",
      "basis": "Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.",
      "condition_origin": "These evidence conditions concern the existing question of oral single-ingredient vitamin C and brachial FMD in adults at cardiovascular risk. They do not establish new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original between-group estimates, variance, CIs, denominators, model and units are needed. The prior value is not converted into relative percent or clinical risk reduction. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N12",
      "question_type": "Evidence condition",
      "question": "Are the hypertension sample of 39 and acute/1-month null result retained?",
      "needed": "R02 direct FMD result, group denominators and CIs",
      "role": "Required",
      "role_reason": "Material on R02 direct FMD result, group denominators and CIs is needed to connect oral single-ingredient treatment, populations, comparators, vascular tests, time points, denominators, precision and harms.",
      "application_exception": "Existing C50, caution, assessment axes and empty values are retained. Oral and intravenous use, single and combined ingredients, acute and sustained outcomes, populations and vascular tests, and percentage points and relative percent are distinguished. No new effects, CIs, denominators, incidence, unique totals or recommended doses are calculated.",
      "criterion": "Original records on R02 direct FMD result, group denominators and CIs must link to the same product, population, comparator, test, time point and denominator, distinguishing acute from sustained outcomes and direct findings from supporting or boundary material.",
      "basis": "Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.",
      "condition_origin": "These evidence conditions concern the existing question of oral single-ingredient vitamin C and brachial FMD in adults at cardiovascular risk. They do not establish new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original group flow, FMD time points/denominators, estimates/CIs, variance and model tables are needed. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N13",
      "question_type": "Evidence condition",
      "question": "Is the B1-related cohort excluded from new independent replication counts?",
      "needed": "Sample linkage between hypertension FMD and related BP reports",
      "role": "Required",
      "role_reason": "Material on Sample linkage between hypertension FMD and related BP reports is needed to connect oral single-ingredient treatment, populations, comparators, vascular tests, time points, denominators, precision and harms.",
      "application_exception": "Existing C50, caution, assessment axes and empty values are retained. Oral and intravenous use, single and combined ingredients, acute and sustained outcomes, populations and vascular tests, and percentage points and relative percent are distinguished. No new effects, CIs, denominators, incidence, unique totals or recommended doses are calculated.",
      "criterion": "Original records on Sample linkage between hypertension FMD and related BP reports must link to the same product, population, comparator, test, time point and denominator, distinguishing acute from sustained outcomes and direct findings from supporting or boundary material.",
      "basis": "Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.",
      "condition_origin": "These evidence conditions concern the existing question of oral single-ingredient vitamin C and brachial FMD in adults at cardiovascular risk. They do not establish new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original institutions/periods, registration, samples, groups/denominators and report links are needed. Other verdict files or participants are not added here. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N14",
      "question_type": "Evidence condition",
      "question": "What are the smoker sample of 20 and acute image exclusion?",
      "needed": "R03 crossover/period-specific allocation, analysis and image-quality denominators",
      "role": "Required",
      "role_reason": "Material on R03 crossover/period-specific allocation, analysis and image-quality denominators is needed to connect oral single-ingredient treatment, populations, comparators, vascular tests, time points, denominators, precision and harms.",
      "application_exception": "Existing C50, caution, assessment axes and empty values are retained. Oral and intravenous use, single and combined ingredients, acute and sustained outcomes, populations and vascular tests, and percentage points and relative percent are distinguished. No new effects, CIs, denominators, incidence, unique totals or recommended doses are calculated.",
      "criterion": "Original records on R03 crossover/period-specific allocation, analysis and image-quality denominators must link to the same product, population, comparator, test, time point and denominator, distinguishing acute from sustained outcomes and direct findings from supporting or boundary material.",
      "basis": "Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.",
      "condition_origin": "These evidence conditions concern the existing question of oral single-ingredient vitamin C and brachial FMD in adults at cardiovascular risk. They do not establish new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original sequence/period flow, image exclusions, acute/8-week denominators and baseline/missingness rules are needed. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N15",
      "question_type": "Evidence condition",
      "question": "Is acute FMD in smokers separated from sustained results?",
      "needed": "R03 original acute mean±SD, P value and contrast",
      "role": "Required",
      "role_reason": "Material on R03 original acute mean±SD, P value and contrast is needed to connect oral single-ingredient treatment, populations, comparators, vascular tests, time points, denominators, precision and harms.",
      "application_exception": "Existing C50, caution, assessment axes and empty values are retained. Oral and intravenous use, single and combined ingredients, acute and sustained outcomes, populations and vascular tests, and percentage points and relative percent are distinguished. No new effects, CIs, denominators, incidence, unique totals or recommended doses are calculated.",
      "criterion": "Original records on R03 original acute mean±SD, P value and contrast must link to the same product, population, comparator, test, time point and denominator, distinguishing acute from sustained outcomes and direct findings from supporting or boundary material.",
      "basis": "Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.",
      "condition_origin": "These evidence conditions concern the existing question of oral single-ingredient vitamin C and brachial FMD in adults at cardiovascular risk. They do not establish new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original acute groups/periods, time points, adjustment/contrasts, denominators/intervals and dispersion tables are needed. No new difference is calculated. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N16",
      "question_type": "Evidence condition",
      "question": "Are the smoker 8-week placebo contrast and SD discrepancy retained?",
      "needed": "Approximately 3.9% at 8 weeks, P=.26 and body/abstract SD",
      "role": "Required",
      "role_reason": "Material on Approximately 3.9% at 8 weeks, P=.26 and body/abstract SD is needed to connect oral single-ingredient treatment, populations, comparators, vascular tests, time points, denominators, precision and harms.",
      "application_exception": "Existing C50, caution, assessment axes and empty values are retained. Oral and intravenous use, single and combined ingredients, acute and sustained outcomes, populations and vascular tests, and percentage points and relative percent are distinguished. No new effects, CIs, denominators, incidence, unique totals or recommended doses are calculated.",
      "criterion": "Original records on Approximately 3.9% at 8 weeks, P=.26 and body/abstract SD must link to the same product, population, comparator, test, time point and denominator, distinguishing acute from sustained outcomes and direct findings from supporting or boundary material.",
      "basis": "Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.",
      "condition_origin": "These evidence conditions concern the existing question of oral single-ingredient vitamin C and brachial FMD in adults at cardiovascular risk. They do not establish new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original body/tables/abstract, groups/time points, denominators, corrections/dispersion and CIs are needed. The unresolved record is retained without new external comparison or numerical calculation. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N17",
      "question_type": "Evidence condition",
      "question": "Are acute, sustained and different populations kept apart as replication?",
      "needed": "Direct replication under the same formulation, diagnosis and duration, and heterogeneity",
      "role": "Required",
      "role_reason": "Material on Direct replication under the same formulation, diagnosis and duration, and heterogeneity is needed to connect oral single-ingredient treatment, populations, comparators, vascular tests, time points, denominators, precision and harms.",
      "application_exception": "Existing C50, caution, assessment axes and empty values are retained. Oral and intravenous use, single and combined ingredients, acute and sustained outcomes, populations and vascular tests, and percentage points and relative percent are distinguished. No new effects, CIs, denominators, incidence, unique totals or recommended doses are calculated.",
      "criterion": "Original records on Direct replication under the same formulation, diagnosis and duration, and heterogeneity must link to the same product, population, comparator, test, time point and denominator, distinguishing acute from sustained outcomes and direct findings from supporting or boundary material.",
      "basis": "Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.",
      "condition_origin": "These evidence conditions concern the existing question of oral single-ingredient vitamin C and brachial FMD in adults at cardiovascular risk. They do not establish new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original disease, baseline, formulation, duration, estimand and effect/denominator links are needed. No new pooled effect or independent replication count is created. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N18",
      "question_type": "Evidence condition",
      "question": "Is the 2014 review of 44 RCTs kept distinct from 44 oral brachial FMD trials?",
      "needed": "Ashor review routes, vascular tests, populations and included trials",
      "role": "Required",
      "role_reason": "Material on Ashor review routes, vascular tests, populations and included trials is needed to connect oral single-ingredient treatment, populations, comparators, vascular tests, time points, denominators, precision and harms.",
      "application_exception": "Existing C50, caution, assessment axes and empty values are retained. Oral and intravenous use, single and combined ingredients, acute and sustained outcomes, populations and vascular tests, and percentage points and relative percent are distinguished. No new effects, CIs, denominators, incidence, unique totals or recommended doses are calculated.",
      "criterion": "Original records on Ashor review routes, vascular tests, populations and included trials must link to the same product, population, comparator, test, time point and denominator, distinguishing acute from sustained outcomes and direct findings from supporting or boundary material.",
      "basis": "Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.",
      "condition_origin": "These evidence conditions concern the existing question of oral single-ingredient vitamin C and brachial FMD in adults at cardiovascular risk. They do not establish new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original oral/intravenous, test/site, disease and duration-specific eligibility, extraction and shared-trial tables are needed. The review is not added as a new primary trial or summed. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N19",
      "question_type": "Evidence condition",
      "question": "Is the sustained oral null-result diabetes citation kept distinct from FMD?",
      "needed": "Darko report test/site, exposure, comparator and denominator",
      "role": "Required",
      "role_reason": "Material on Darko report test/site, exposure, comparator and denominator is needed to connect oral single-ingredient treatment, populations, comparators, vascular tests, time points, denominators, precision and harms.",
      "application_exception": "Existing C50, caution, assessment axes and empty values are retained. Oral and intravenous use, single and combined ingredients, acute and sustained outcomes, populations and vascular tests, and percentage points and relative percent are distinguished. No new effects, CIs, denominators, incidence, unique totals or recommended doses are calculated.",
      "criterion": "Original records on Darko report test/site, exposure, comparator and denominator must link to the same product, population, comparator, test, time point and denominator, distinguishing acute from sustained outcomes and direct findings from supporting or boundary material.",
      "basis": "Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.",
      "condition_origin": "These evidence conditions concern the existing question of oral single-ingredient vitamin C and brachial FMD in adults at cardiovascular risk. They do not establish new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original vascular test, site, method, exposure and outcome/denominator tables are needed. Direct versus boundary relevance to FMD remains awaiting content review. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N20",
      "question_type": "Evidence condition",
      "question": "Are FMD measurement, units and endothelial dependence known?",
      "needed": "Brachial ultrasound, baseline diameter, dilation percentage and assessment/time rules",
      "role": "Required",
      "role_reason": "Material on Brachial ultrasound, baseline diameter, dilation percentage and assessment/time rules is needed to connect oral single-ingredient treatment, populations, comparators, vascular tests, time points, denominators, precision and harms.",
      "application_exception": "Existing C50, caution, assessment axes and empty values are retained. Oral and intravenous use, single and combined ingredients, acute and sustained outcomes, populations and vascular tests, and percentage points and relative percent are distinguished. No new effects, CIs, denominators, incidence, unique totals or recommended doses are calculated.",
      "criterion": "Original records on Brachial ultrasound, baseline diameter, dilation percentage and assessment/time rules must link to the same product, population, comparator, test, time point and denominator, distinguishing acute from sustained outcomes and direct findings from supporting or boundary material.",
      "basis": "Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.",
      "condition_origin": "These evidence conditions concern the existing question of oral single-ingredient vitamin C and brachial FMD in adults at cardiovascular risk. They do not establish new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original ultrasound/occlusion, premeasurement conditions, assessors/reliability, baseline diameter, time points and analysis plans are needed. No new unit conversion or mechanism is established. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N21",
      "question_type": "Evidence condition",
      "question": "What allocation, blinding and crossover methods applied?",
      "needed": "Original CAD/hypertension parallel and smoker crossover methods",
      "role": "Required",
      "role_reason": "Material on Original CAD/hypertension parallel and smoker crossover methods is needed to connect oral single-ingredient treatment, populations, comparators, vascular tests, time points, denominators, precision and harms.",
      "application_exception": "Existing C50, caution, assessment axes and empty values are retained. Oral and intravenous use, single and combined ingredients, acute and sustained outcomes, populations and vascular tests, and percentage points and relative percent are distinguished. No new effects, CIs, denominators, incidence, unique totals or recommended doses are calculated.",
      "criterion": "Original records on Original CAD/hypertension parallel and smoker crossover methods must link to the same product, population, comparator, test, time point and denominator, distinguishing acute from sustained outcomes and direct findings from supporting or boundary material.",
      "basis": "Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.",
      "condition_origin": "These evidence conditions concern the existing question of oral single-ingredient vitamin C and brachial FMD in adults at cardiovascular risk. They do not establish new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original sequence, concealment, assessors/blinding, washout/period effects, crossover sets and methods are needed. No formal RoB2/GRADE is produced. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N22",
      "question_type": "Evidence condition",
      "question": "Were prior endpoints, all time points and selective reporting checked?",
      "needed": "Acute/sustained FMD hierarchy, registration/plans and multiplicity",
      "role": "Required",
      "role_reason": "Material on Acute/sustained FMD hierarchy, registration/plans and multiplicity is needed to connect oral single-ingredient treatment, populations, comparators, vascular tests, time points, denominators, precision and harms.",
      "application_exception": "Existing C50, caution, assessment axes and empty values are retained. Oral and intravenous use, single and combined ingredients, acute and sustained outcomes, populations and vascular tests, and percentage points and relative percent are distinguished. No new effects, CIs, denominators, incidence, unique totals or recommended doses are calculated.",
      "criterion": "Original records on Acute/sustained FMD hierarchy, registration/plans and multiplicity must link to the same product, population, comparator, test, time point and denominator, distinguishing acute from sustained outcomes and direct findings from supporting or boundary material.",
      "basis": "Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.",
      "condition_origin": "These evidence conditions concern the existing question of oral single-ingredient vitamin C and brachial FMD in adults at cardiovascular risk. They do not establish new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original registration, protocol/SAP, all time points/endpoints, corrections and plan changes are needed. Preregistration or complete compliance is not newly assigned. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N23",
      "question_type": "Evidence condition",
      "question": "What is the impact of missingness, image exclusions and analysis sets?",
      "needed": "Group/period flow, measurement missingness, exclusions and handling",
      "role": "Required",
      "role_reason": "Material on Group/period flow, measurement missingness, exclusions and handling is needed to connect oral single-ingredient treatment, populations, comparators, vascular tests, time points, denominators, precision and harms.",
      "application_exception": "Existing C50, caution, assessment axes and empty values are retained. Oral and intravenous use, single and combined ingredients, acute and sustained outcomes, populations and vascular tests, and percentage points and relative percent are distinguished. No new effects, CIs, denominators, incidence, unique totals or recommended doses are calculated.",
      "criterion": "Original records on Group/period flow, measurement missingness, exclusions and handling must link to the same product, population, comparator, test, time point and denominator, distinguishing acute from sustained outcomes and direct findings from supporting or boundary material.",
      "basis": "Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.",
      "condition_origin": "These evidence conditions concern the existing question of oral single-ingredient vitamin C and brachial FMD in adults at cardiovascular risk. They do not establish new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original flow, image/measurement missingness, attrition/exclusion reasons, ITT/crossover completers, handling and sensitivity material are needed. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N24",
      "question_type": "Evidence condition",
      "question": "Are BP, glycaemia and myocardial infarction/stroke excluded from FMD confirmation?",
      "needed": "Direct material on other indications/endpoints and clinical events",
      "role": "Supplementary",
      "role_reason": "Material on Direct material on other indications/endpoints and clinical events is needed to connect oral single-ingredient treatment, populations, comparators, vascular tests, time points, denominators, precision and harms.",
      "application_exception": "Existing C50, caution, assessment axes and empty values are retained. Oral and intravenous use, single and combined ingredients, acute and sustained outcomes, populations and vascular tests, and percentage points and relative percent are distinguished. No new effects, CIs, denominators, incidence, unique totals or recommended doses are calculated.",
      "criterion": "Original records on Direct material on other indications/endpoints and clinical events must link to the same product, population, comparator, test, time point and denominator, distinguishing acute from sustained outcomes and direct findings from supporting or boundary material.",
      "basis": "Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.",
      "condition_origin": "These evidence conditions concern the existing question of oral single-ingredient vitamin C and brachial FMD in adults at cardiovascular risk. They do not establish new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Direct research on each clinical or other endpoint is separately needed. Other pages/grades and reports from the same sample are not newly added. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N25",
      "question_type": "Evidence condition",
      "question": "Are the four company-involvement pathways preserved by report?",
      "needed": "Funding, product/placebo support, employee authors and COI",
      "role": "Required",
      "role_reason": "Material on Funding, product/placebo support, employee authors and COI is needed to connect oral single-ingredient treatment, populations, comparators, vascular tests, time points, denominators, precision and harms.",
      "application_exception": "Existing C50, caution, assessment axes and empty values are retained. Oral and intravenous use, single and combined ingredients, acute and sustained outcomes, populations and vascular tests, and percentage points and relative percent are distinguished. No new effects, CIs, denominators, incidence, unique totals or recommended doses are calculated.",
      "criterion": "Original records on Funding, product/placebo support, employee authors and COI must link to the same product, population, comparator, test, time point and denominator, distinguishing acute from sustained outcomes and direct findings from supporting or boundary material.",
      "basis": "Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.",
      "condition_origin": "These evidence conditions concern the existing question of oral single-ingredient vitamin C and brachial FMD in adults at cardiovascular risk. They do not establish new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original support/fellowships, product provision, affiliations and COI are needed. Overall I2 and specific I1 do not overwrite each other or establish absence of company involvement. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N26",
      "question_type": "Evidence condition",
      "question": "Are 5 reports, shared cohorts and unique trials/participants distinguished?",
      "needed": "3 primary-trial reports, 2 review/diabetes citations and overlap/sharing",
      "role": "Required",
      "role_reason": "Material on 3 primary-trial reports, 2 review/diabetes citations and overlap/sharing is needed to connect oral single-ingredient treatment, populations, comparators, vascular tests, time points, denominators, precision and harms.",
      "application_exception": "Existing C50, caution, assessment axes and empty values are retained. Oral and intravenous use, single and combined ingredients, acute and sustained outcomes, populations and vascular tests, and percentage points and relative percent are distinguished. No new effects, CIs, denominators, incidence, unique totals or recommended doses are calculated.",
      "criterion": "Original records on 3 primary-trial reports, 2 review/diabetes citations and overlap/sharing must link to the same product, population, comparator, test, time point and denominator, distinguishing acute from sustained outcomes and direct findings from supporting or boundary material.",
      "basis": "Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.",
      "condition_origin": "These evidence conditions concern the existing question of oral single-ingredient vitamin C and brachial FMD in adults at cardiovascular risk. They do not establish new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original report/trial map, registration, institutions/periods, participants, products/teams and inclusion tables are needed. No new totals or independence is established. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N27",
      "question_type": "Evidence condition",
      "question": "Are harm collection, events and discontinuation known?",
      "needed": "Gastrointestinal effects, collection, events/discontinuation and severity",
      "role": "Supplementary",
      "role_reason": "Material on Gastrointestinal effects, collection, events/discontinuation and severity is needed to connect oral single-ingredient treatment, populations, comparators, vascular tests, time points, denominators, precision and harms.",
      "application_exception": "Existing C50, caution, assessment axes and empty values are retained. Oral and intravenous use, single and combined ingredients, acute and sustained outcomes, populations and vascular tests, and percentage points and relative percent are distinguished. No new effects, CIs, denominators, incidence, unique totals or recommended doses are calculated.",
      "criterion": "Original records on Gastrointestinal effects, collection, events/discontinuation and severity must link to the same product, population, comparator, test, time point and denominator, distinguishing acute from sustained outcomes and direct findings from supporting or boundary material.",
      "basis": "Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.",
      "condition_origin": "These evidence conditions concern the existing question of oral single-ingredient vitamin C and brachial FMD in adults at cardiovascular risk. They do not establish new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original harm methods, events/discontinuation, missingness and comparator data are needed. Unread material is not treated as no harm. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N28",
      "question_type": "Evidence condition",
      "question": "What are harm denominators, acute/sustained exposure and comparators?",
      "needed": "Safety sets, actual treatment, period/group events and crossover exposure",
      "role": "Supplementary",
      "role_reason": "Material on Safety sets, actual treatment, period/group events and crossover exposure is needed to connect oral single-ingredient treatment, populations, comparators, vascular tests, time points, denominators, precision and harms.",
      "application_exception": "Existing C50, caution, assessment axes and empty values are retained. Oral and intravenous use, single and combined ingredients, acute and sustained outcomes, populations and vascular tests, and percentage points and relative percent are distinguished. No new effects, CIs, denominators, incidence, unique totals or recommended doses are calculated.",
      "criterion": "Original records on Safety sets, actual treatment, period/group events and crossover exposure must link to the same product, population, comparator, test, time point and denominator, distinguishing acute from sustained outcomes and direct findings from supporting or boundary material.",
      "basis": "Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.",
      "condition_origin": "These evidence conditions concern the existing question of oral single-ingredient vitamin C and brachial FMD in adults at cardiovascular risk. They do not establish new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Group/period safety denominators, exposure/discontinuation, events, comparators and same-participant links are needed. Incidence is not calculated. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N29",
      "question_type": "Evidence condition",
      "question": "What is known about coadministration, kidney/stone risk, iron overload and long-term harms?",
      "needed": "Vulnerable populations, coadministration/alternative causes and independent/rare/long-term harms",
      "role": "Supplementary",
      "role_reason": "Material on Vulnerable populations, coadministration/alternative causes and independent/rare/long-term harms is needed to connect oral single-ingredient treatment, populations, comparators, vascular tests, time points, denominators, precision and harms.",
      "application_exception": "Existing C50, caution, assessment axes and empty values are retained. Oral and intravenous use, single and combined ingredients, acute and sustained outcomes, populations and vascular tests, and percentage points and relative percent are distinguished. No new effects, CIs, denominators, incidence, unique totals or recommended doses are calculated.",
      "criterion": "Original records on Vulnerable populations, coadministration/alternative causes and independent/rare/long-term harms must link to the same product, population, comparator, test, time point and denominator, distinguishing acute from sustained outcomes and direct findings from supporting or boundary material.",
      "basis": "Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.",
      "condition_origin": "These evidence conditions concern the existing question of oral single-ingredient vitamin C and brachial FMD in adults at cardiovascular risk. They do not establish new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Coadministration/baseline, event timing/course, independent reports, vulnerable groups, longer exposure and denominators are needed. No new harm search or judgment is performed. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N30",
      "question_type": "Evidence condition",
      "question": "Are past abstract/index/body checks distinguished from current unread material?",
      "needed": "Historical access wording, stored summary and external abstracts/full text/registration/plans",
      "role": "Required",
      "role_reason": "Material on Historical access wording, stored summary and external abstracts/full text/registration/plans is needed to connect oral single-ingredient treatment, populations, comparators, vascular tests, time points, denominators, precision and harms.",
      "application_exception": "Existing C50, caution, assessment axes and empty values are retained. Oral and intravenous use, single and combined ingredients, acute and sustained outcomes, populations and vascular tests, and percentage points and relative percent are distinguished. No new effects, CIs, denominators, incidence, unique totals or recommended doses are calculated.",
      "criterion": "Original records on Historical access wording, stored summary and external abstracts/full text/registration/plans must link to the same product, population, comparator, test, time point and denominator, distinguishing acute from sustained outcomes and direct findings from supporting or boundary material.",
      "basis": "Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.",
      "condition_origin": "These evidence conditions concern the existing question of oral single-ingredient vitamin C and brachial FMD in adults at cardiovascular risk. They do not establish new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: External unread status is retained until acquisition and content review. Historical verification or URLs are not promoted into current reading or completed QA. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N31",
      "question_type": "Evidence condition",
      "question": "Are Korean/English text, empty corrections and prior calculation/discrepancy preserved?",
      "needed": "Complete originals, empty correction/subclaim arrays and calculation/SD difference",
      "role": "Supplementary",
      "role_reason": "Material on Complete originals, empty correction/subclaim arrays and calculation/SD difference is needed to connect oral single-ingredient treatment, populations, comparators, vascular tests, time points, denominators, precision and harms.",
      "application_exception": "Existing C50, caution, assessment axes and empty values are retained. Oral and intravenous use, single and combined ingredients, acute and sustained outcomes, populations and vascular tests, and percentage points and relative percent are distinguished. No new effects, CIs, denominators, incidence, unique totals or recommended doses are calculated.",
      "criterion": "Original records on Complete originals, empty correction/subclaim arrays and calculation/SD difference must link to the same product, population, comparator, test, time point and denominator, distinguishing acute from sustained outcomes and direct findings from supporting or boundary material.",
      "basis": "Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.",
      "condition_origin": "These evidence conditions concern the existing question of oral single-ingredient vitamin C and brachial FMD in adults at cardiovascular risk. They do not establish new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: After content review, new material, corrections or verdict changes are recorded as separate events. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N32",
      "question_type": "Evidence condition",
      "question": "Are original C50, EX/CX, axes and evidence date distinct from production?",
      "needed": "Original C50, caution, assessment axes and evidence date",
      "role": "Required",
      "role_reason": "Material on Original C50, caution, assessment axes and evidence date is needed to connect oral single-ingredient treatment, populations, comparators, vascular tests, time points, denominators, precision and harms.",
      "application_exception": "Existing C50, caution, assessment axes and empty values are retained. Oral and intravenous use, single and combined ingredients, acute and sustained outcomes, populations and vascular tests, and percentage points and relative percent are distinguished. No new effects, CIs, denominators, incidence, unique totals or recommended doses are calculated.",
      "criterion": "Original records on Original C50, caution, assessment axes and evidence date must link to the same product, population, comparator, test, time point and denominator, distinguishing acute from sustained outcomes and direct findings from supporting or boundary material.",
      "basis": "Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms.",
      "condition_origin": "These evidence conditions concern the existing question of oral single-ingredient vitamin C and brachial FMD in adults at cardiovascular risk. They do not establish new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: New material, condition revisions and verdict changes are separate events after content review. The original date is not used as a current search or external reading date. This records needed materials; no new research was executed."
    }
  ]
}